title: Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China: a study of 10,012 cases from a nationwide working group.
abstract: OBJECTIVE
  About one-third of the world's total annual new cervical cancer cases are found in the People's Republic of China. We investigate the prevalence and clinical characteristics of cervical cancer cases in the People's Republic of China over the past decade.
  
  
  METHODS
  A total of 10,012 hospitalized patients with cervical cancer from regions nationwide were enrolled from 2000 to 2009. Demographic and clinical characteristics, therapeutic strategies, and outcomes were analyzed.
  
  
  RESULTS
  The mean age at diagnosis of all cervical cancer patients was 44.7 ± 9.5 years, which is 5-10 years younger than mean ages reported before 2000 in the People's Republic of China. The age distribution showed 16.0% of patients were ≤35 years old, 41.7% were 35-45 years old, and 41.7% were >45 years old. Early stage diagnoses were most prevalent: 57.3% were stage I, 33.9% were stage II, and 4.3% were stage III or IV. Most patients (83.9%) were treated with surgery, and only 9.5% had radiotherapy alone. Among 8,405 patients treated with surgery, 68.6% received adjuvant treatments, including chemotherapy (20.9%), radiotherapy (26.0%), and chemoradiotherapy (21.9%). Among stage IA patients, 16.0% were treated with corpus uteri preservation. The proportion of ovarian preservation was 42.0%.
  
  
  CONCLUSIONS
  Cervical cancer cases in the People's Republic of China show increasing prevalence in young patients and at early stages. In the past 10 years, surgery has become the dominant treatment and is increasingly combined with adjuvant chemotherapy for patients with stages I and II. Conservative surgical approaches are reasonable options for genital organ preservation in selected patients.
authors.affiliation: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China;
authors.forename: Shuang
authors.initials: S
authors.lastname: Li
authors.forename: Ting
authors.initials: T
authors.lastname: Hu
authors.forename: Weiguo
authors.initials: W
authors.lastname: Lv
authors.forename: Hang
authors.initials: H
authors.lastname: Zhou
authors.forename: Xiong
authors.initials: X
authors.lastname: Li
authors.forename: Ru
authors.initials: R
authors.lastname: Yang
authors.forename: Yao
authors.initials: Y
authors.lastname: Jia
authors.forename: Kecheng
authors.initials: K
authors.lastname: Huang
authors.forename: Zhilan
authors.initials: Z
authors.lastname: Chen
authors.forename: Shaoshuai
authors.initials: S
authors.lastname: Wang
authors.forename: Fangxu
authors.initials: F
authors.lastname: Tang
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Shen
authors.forename: Jin
authors.initials: J
authors.lastname: Zhou
authors.forename: Ling
authors.initials: L
authors.lastname: Xi
authors.forename: Dongrui
authors.initials: D
authors.lastname: Deng
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Shixuan
authors.initials: S
authors.lastname: Wang
authors.forename: Xing
authors.initials: X
authors.lastname: Xie
authors.forename: Ding
authors.initials: D
authors.lastname: Ma
mesh_terms: D000328:Adult; D017024:Chemotherapy, Adjuvant; D002681:China; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery*
keywords: Cervical cancer; Clinical feature; Surgery; Survival rate; Therapeutic strategies
references.citation: Gynecol Oncol. 1996 Sep;62(3):344-52
references.pmid: 8812531
references.citation: Cancer. 1989 Nov 15;64(10):2184-90
references.pmid: 2804908
references.citation: Cancer. 2008 Mar 15;112(6):1264-71
references.pmid: 18257090
references.citation: Acta Radiol Oncol Radiat Phys Biol. 1979;18(5):465-9
references.pmid: 532695
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7428-36
references.pmid: 16234510
references.citation: Int J Cancer. 2012 Feb 1;130(3):641-52
references.pmid: 21387308
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):677-86
references.pmid: 15767349
references.citation: Ann Surg Oncol. 2013 Mar;20(3):881-90
references.pmid: 23054110
references.citation: Gynecol Oncol. 2005 May;97(2):550-8
references.pmid: 15863159
references.citation: Obstet Gynecol. 1975 Nov;46(5):507-10
references.pmid: 1196552
references.citation: Eur J Cancer Prev. 2005 Dec;14(6):513-8
references.pmid: 16284495
references.citation: Cancer. 1995 Nov 15;76(10 Suppl):1934-47
references.pmid: 8634985
references.citation: Asian Pac J Cancer Prev. 2011;12(8):1985-8
references.pmid: 22292638
references.citation: Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):82-9
references.pmid: 18400358
references.citation: J Clin Oncol. 2008 Dec 10;26(35):5802-12
references.pmid: 19001332
references.citation: Cancer. 1988 Oct 15;62(8):1586-93
references.pmid: 3167773
references.citation: J Community Health. 2012 Feb;37(1):217-23
references.pmid: 21773819
references.citation: Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):457-62
references.pmid: 19640191
references.citation: Am J Obstet Gynecol. 2000 Aug;183(2):407-13
references.pmid: 10942478
references.citation: Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-103
references.pmid: 17161167
references.citation: Eur J Cancer. 2002 Oct;38(15):2041-7
references.pmid: 12376210
references.citation: Jpn J Clin Oncol. 2004 Feb;34(2):99-103
references.pmid: 15067104
references.citation: Di Yi Jun Yi Da Xue Xue Bao. 2005 Jun;25(6):605-9
references.pmid: 15958289
references.citation: Cancer. 2008 Nov 15;113(10 Suppl):2955-63
references.pmid: 18980279
references.citation: Neoplasma. 1976;23(2):215-21
references.pmid: 934390
references.citation: J Epidemiol Community Health. 1980 Mar;34(1):14-8
references.pmid: 7365390
references.citation: Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S49-51
references.pmid: 21053528
references.citation: Gynecol Oncol. 1985 Mar;20(3):378-86
references.pmid: 3972296
references.citation: Br J Obstet Gynaecol. 1976 Jul;83(7):560-6
references.pmid: 952785
references.citation: Eur J Cancer. 2012 Oct;48(15):2353-60
references.pmid: 22503395
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Acta Obstet Gynecol Scand Suppl. 1977;68:1-42
references.pmid: 272115
references.citation: Int J Gynaecol Obstet. 2009 May;105(2):107-8
references.pmid: 19342051
references.citation: Cancer. 2011 Jan 15;117(2):310-7
references.pmid: 20862747
references.citation: Cancer Epidemiol. 2012 Aug;36(4):384-90
references.pmid: 22377277
references.citation: Cancer. 2008 Nov 15;113(10 Suppl):2855-64
references.pmid: 18980204
references.citation: Acta Pathol Microbiol Immunol Scand A. 1982 Mar;90(2):139-43
references.pmid: 7080821
references.citation: Int J Gynecol Cancer. 2010 Oct;20(7):1240-3
references.pmid: 21495238
references.citation: J Clin Oncol. 2004 Mar 1;22(5):872-80
references.pmid: 14990643